1-20 of 119 Search Results for

compusyn-software

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5951.
Published: 15 June 2022
... viability assay results of EC cells treated with drugs individually and in combination using CompuSyn software. ATP, soft-agar colony formation and invasion assays were performed to evaluate the combined drug effects on cell viability, anchorage independent colony formation and invasion properties...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3994.
Published: 15 June 2022
.... Drug combination (OST+PERK/IRE1 inhibitor) studies were performed using MTT assay to validate the CRISPR screen targets, where the drug combination synergy quantification was determined using COMPUSYN software. Outcomes of inhibitor treatment were analyzed using western blot and PCR assay. Results...
Images
EZH2 inhibition enhances apoptosis of cytotoxic agent–treated AML cells.  A...
Published: 02 February 2022
Figure 3. EZH2 inhibition enhances apoptosis of cytotoxic agent–treated AML cells. A, THP-1, KG-1, and CD34+ AML primary cells (sample #40) were treated with doxorubicin alone (0.1, 0.3, or 0.5 μmol/L), or in combination with GSK126 (5 μmol/L), for 48 hours. Apoptosis (caspase-3/7 activity) was analyzed by flow cytometry. Graph bars represent fold change ± SEM in the percentage of caspase-3/7 activation over the untreated control. Unpaired t test: *, P < 0.05; **, P < 0.01; ***, P < 0.001; B, Combination Indexes (C.I.) of GSK126/doxorubicin-induced apoptosis in THP-1 and KG-1 cells. THP-1 or KG-1 cells were treated with three different concentrations of GSK126 and/or doxorubicin. Left, dose–response matrices showing the percentage of viable cells (±SEM) after treatment with increasing doses of doxorubicin, GSK126, and combinations of drug pair doxorubicin/GSK126. Colors in the dose–response matrices indicate different levels of responses (from white to red, decreasing viable cells) of THP-1 and KG-1 cells. Right, viability data elaborated using CompuSyn software to calculate C.I. plotted on the y-axis of a 2D graph. The x-axes show increasing concentrations of doxorubicin, whereas the different colors indicate increasing concentrations of GSK126 (see labels). C.I. = 0.90–1.10 indicates additive effects; C.I. = 0.1–0.9 indicates synergistic effects. C, H3K27me3 accumulation on nascent DNA (left) and caspase-3/7 activation in AML sample #40 CD34+CD38high or CD34+CD38low cells treated with GSK126 (5 μmol/L), doxorubicin (0.1 μmol/L), or the two drugs in combination. Figure 3. EZH2 inhibition enhances apoptosis of cytotoxic agent–treated AML cells. A, THP-1, KG-1, and CD34+ AML primary cells (sample #40) were treated with doxorubicin alone (0.1, 0.3, or 0.5 μmol/L), or in combination with GSK126 (5 μmol/L), for 48 hours. Apoptosis (caspase-3/7 activity) was analyzed by flow cytometry. Graph bars represent fold change ± SEM in the percentage of caspase-3/7 activation over the untreated control. Unpaired t test: *, P < 0.05; **, P < 0.01; ***, P < 0.001; B, Combination Indexes (C.I.) of GSK126/doxorubicin-induced apoptosis in THP-1 and KG-1 cells. THP-1 or KG-1 cells were treated with three different concentrations of GSK126 and/or doxorubicin. Left, dose–response matrices showing the percentage of viable cells (±SEM) after treatment with increasing doses of doxorubicin, GSK126, and combinations of drug pair doxorubicin/GSK126. Colors in the dose–response matrices indicate different levels of responses (from white to red, decreasing viable cells) of THP-1 and KG-1 cells. Right, viability data elaborated using CompuSyn software to calculate C.I. plotted on the y-axis of a 2D graph. The x-axes show increasing concentrations of doxorubicin, whereas the different colors indicate increasing concentrations of GSK126 (see labels). C.I. = 0.90–1.10 indicates additive effects; C.I. = 0.1–0.9 indicates synergistic effects. C, H3K27me3 accumulation on nascent DNA (left) and caspase-3/7 activation in AML sample #40 CD34+CD38high or CD34+CD38low cells treated with GSK126 (5 μmol/L), doxorubicin (0.1 μmol/L), or the two drugs in combination. More
Journal Articles
Cancer Res (2022) 82 (11): 2110–2123.
Published: 06 June 2022
... are shown. Scale bar, 50 μm. J, Compusyn was used to calculate the combination index (CI) for cells that were treated with palbociclib (Palbo) and enzalutamide for 4 days. K, Western blot analysis of LNCaP-sgNC and LNCaP-sgPRRX2 cells treated with enzalutamide (5 μmol/L) or grown in CSS media for 7 days...
Includes: Supplementary data
Images
PIM inhibition potentiates CDC and ADCP of rituximab. Increased CDC trigger...
Published: 01 December 2021
Figure 5. PIM inhibition potentiates CDC and ADCP of rituximab. Increased CDC triggered by rituximab in MEN1703-treated cells. DHL4 and RAJI were pretreated with DMSO or 1.5 μmol/L MEN1703 for 48 hours and then treated with rituximab (1 hour) in the presence of human AB Rh+ serum. Cell death was determined with PI staining and flow cytometry. Error bars, ±SD of two independent replicates in a representative experiment. Combination indexes (CI) were calculated using CompuSyn software. Statistical significance was determined using two-way ANOVA. B, PIM inhibition in DLBCL cells potentiates rituximab-dependent phagocytosis. After 72 hours of treatment with DMSO or MEN1703 (1 μmol/L), CFSE-labeled DHL4 and DHL6 cells were incubated with human peripheral blood–derived macrophages in the presence of IgG isotype control or rituximab (1 μg/mL). Presence of fluorescently labeled DLBCL cells within the macrophages was assessed by immunofluorescence microscopy (arrows). Bar graphs present the mean phagocytic index, determined as the number of ingested cells per 100 macrophages. Error bars, ±SD of three independent replicates in a representative experiment. P values were determined using the two-sided t test: **, P < 0.01. Data in A–B are representative of three independent experiments. Figure 5. PIM inhibition potentiates CDC and ADCP of rituximab. Increased CDC triggered by rituximab in MEN1703-treated cells. DHL4 and RAJI were pretreated with DMSO or 1.5 μmol/L MEN1703 for 48 hours and then treated with rituximab (1 hour) in the presence of human AB Rh+ serum. Cell death was determined with PI staining and flow cytometry. Error bars, ±SD of two independent replicates in a representative experiment. Combination indexes (CI) were calculated using CompuSyn software. Statistical significance was determined using two-way ANOVA. B, PIM inhibition in DLBCL cells potentiates rituximab-dependent phagocytosis. After 72 hours of treatment with DMSO or MEN1703 (1 μmol/L), CFSE-labeled DHL4 and DHL6 cells were incubated with human peripheral blood–derived macrophages in the presence of IgG isotype control or rituximab (1 μg/mL). Presence of fluorescently labeled DLBCL cells within the macrophages was assessed by immunofluorescence microscopy (arrows). Bar graphs present the mean phagocytic index, determined as the number of ingested cells per 100 macrophages. Error bars, ±SD of three independent replicates in a representative experiment. P values were determined using the two-sided t test: **, P < 0.01. Data in A–B are representative of three independent experiments. More
Journal Articles
Cancer Res (2022) 82 (3): 458–471.
Published: 02 February 2022
... of drug pair doxorubicin/GSK126. Colors in the dose–response matrices indicate different levels of responses (from white to red, decreasing viable cells) of THP-1 and KG-1 cells. Right, viability data elaborated using CompuSyn software to calculate C.I. plotted on the y-axis of a 2D graph...
Includes: Supplementary data
Journal Articles
Cancer Res (2022) 82 (1): 169–176.
Published: 04 January 2022
... with constant ratios of drug combinations (carboplatin and SR11302; paclitaxel and SR11302) in serial dilutions and combination indices calculated with Compusyn software. The data generated in this study are available within the article and its Supplementary Data files. Expression profile data analyzed...
Includes: Supplementary data
Journal Articles
Journal Articles
Cancer Res (2022) 82 (4): 721–733.
Published: 17 December 2021
... avenues for treating this deadly endometrial cancer. For calculations of synergy, Compusyn Software was used ( 25 ). Enzymatically prepared siRNAs (esiRNA) for RRM1, RRM2, or RLUC (control) were purchased from Sigma Aldrich and transfected at a concentration of 3,000 ng esiRNA per 10-cm plate...
Includes: Supplementary data
Images
Synergistic effect of YUM70 in combination with topotecan and vorinostat. M...
Published: 01 April 2021
Figure 6. Synergistic effect of YUM70 in combination with topotecan and vorinostat. MIA PaCa-2 cells were treated with YUM70 with or without topotecan (Topo) and vorinostat (SAHA), at stated concentrations, and kept in culture until colonies were observed in DMSO-treated control. A, A representative image is shown (one concentration). B and C, The number of colonies was quantified using Image Studio ver3.1 software from three independent experiments (more than one concentration). Graphical data is presented as mean ± SD. *, P < 0.05; **, P < 0.01. The P value of the combination was calculated and compared with YUM70 alone. D and E, The combined effect was calculated using CompuSyn software. CI <1 is defined as synergism. F, Combination regimen causes apoptosis in MIA PaCa-2 and PANC-1 cells. Top, cells in the bottom left quadrant of each panel (Annexin V–negative, PI-negative) are viable, whereas cells in the bottom right quadrant (Annexin V–positive, PI-negative) are in the early stage of apoptosis, and cells in the top right quadrant (Annexin V–positive, PI-positive) are in the late stage of apoptosis/necrosis. Bottom, the percentage of apoptotic cells is shown in a histogram. A representative image of three independent experiments is shown. Figure 6. Synergistic effect of YUM70 in combination with topotecan and vorinostat. MIA PaCa-2 cells were treated with YUM70 with or without topotecan (Topo) and vorinostat (SAHA), at stated concentrations, and kept in culture until colonies were observed in DMSO-treated control. A, A representative image is shown (one concentration). B and C, The number of colonies was quantified using Image Studio ver3.1 software from three independent experiments (more than one concentration). Graphical data is presented as mean ± SD. *, P < 0.05; **, P < 0.01. The P value of the combination was calculated and compared with YUM70 alone. D and E, The combined effect was calculated using CompuSyn software. CI <1 is defined as synergism. F, Combination regimen causes apoptosis in MIA PaCa-2 and PANC-1 cells. Top, cells in the bottom left quadrant of each panel (Annexin V–negative, PI-negative) are viable, whereas cells in the bottom right quadrant (Annexin V–positive, PI-negative) are in the early stage of apoptosis, and cells in the top right quadrant (Annexin V–positive, PI-positive) are in the late stage of apoptosis/necrosis. Bottom, the percentage of apoptotic cells is shown in a histogram. A representative image of three independent experiments is shown. More
Journal Articles
Cancer Res (2021) 81 (13_Supplement): LB021.
Published: 01 July 2021
... combo dose-ratios for 2- and 3-drug combos, and the three doses of each of 7 sets, at the dose range of about 1.5-ED50, 1-ED50 and 0.75-ED50, each with >5 patients, using CompuSyn for instant synergy simulations. The benefit for the MAL-PD/CI is that all single drug...
Journal Articles
Cancer Res (2021) 81 (19): 4964–4980.
Published: 01 October 2021
... and l-alanosine were assessed using the Chou-Talalay method with CompuSyn software ( 34 ). Clinical information of TMAs samples was acquired from patients with PDAC who underwent surgical resection at Fudan University Shanghai Cancer Center (FUSCC). All of the patients were informed written...
Includes: Supplementary data
Journal Articles
Cancer Res (2021) 81 (18): 4822–4834.
Published: 15 September 2021
... by sulforhodamine B (SRB) assay as described previously ( 24 ). Combination index (CI) for drug interaction (e.g., synergy) was calculated using CompuSyn software (ComboSyn, Inc.). Apoptosis was detected with an Annexin V/7-AAD Apoptosis Detection Kit (BD Biosciences) following the manufacturer's...
Includes: Supplementary data
Journal Articles
Cancer Res (2020) 80 (16_Supplement): 5407.
Published: 15 August 2020
..., combination studies of ONC201 and panobinostat demonstrated a synergistic effect of both agents, as calculated by CompuSyn software. Combination indices below one were observed at concentrations of 0.003 - 0.05 µM of panobinostat with ONC201 at 0.156 - 5 µM, with the best combination index of 0.22. We...
Journal Articles
Cancer Res (2020) 80 (16_Supplement): 4139.
Published: 15 August 2020
... CompuSyn software. Combination indices (CI) were <1 for the majority of conditions across all cell lines, supporting synergistic interaction. Effects were most pronounced in HCC1395 cells with average CI 0.82. Furthermore, TUNEL assays show that addition of SCH-727965 to ALW significantly increases...
Journal Articles
Cancer Res (2020) 80 (16_Supplement): 1743.
Published: 15 August 2020
... using a four-parameter non-linear regression model, and synergy estimates were derived by Compusyn software. Results: The EpiG screen revealed that as a class BET inhibitors potently limited cell viability in 5637 and J82 cells. Birabresib was particularly potent (IC50 in 5637 cells=100nM...
Journal Articles
Cancer Res (2020) 80 (16_Supplement): 236.
Published: 15 August 2020
.... Interestingly, combination treatments of 6-AN with 5-FU resulted in synergistic effects as estimated using Compusyn software. We used HCT116 colorectal cancer cells resistant to 5-FU (HCT116 5FU-R) or lacking p53, as models for tumor resistance. Importantly, the combination treatment sensitized both HCT116...
Journal Articles
Cancer Res (2021) 81 (13): 3539–3553.
Published: 01 July 2021
... of gefitinib with KRCT-6j in GR-H1993 cells. The synergism was evaluated by the Chou–Talalay method, which calculates a combination index (CI; ref. 36 ). The CI calculated by Compusyn was used to calculate synergism (CI<1), additive effect (CI = 1), and antagonism (CI>1). We used two different...
Includes: Supplementary data
Journal Articles
Cancer Res (2021) 81 (11): 2903–2917.
Published: 01 June 2021
... t test. Results from drug dosage matrices were analyzed using CompuSyn software ( http://www.combosyn.com ) to generate Chou–Talalay combination indexes ( 24 ). Outbred athymic nude mice (#007850) were purchased from The Jackson Laboratory. All procedures were performed under general...
Includes: Supplementary data
Journal Articles
Series: Author Choice
Cancer Res (2021) 81 (7): 1883–1895.
Published: 01 April 2021
... value of the combination was calculated and compared with YUM70 alone. D and E, The combined effect was calculated using CompuSyn software. CI <1 is defined as synergism. F, Combination regimen causes apoptosis in MIA PaCa-2 and PANC-1 cells. Top, cells in the bottom left quadrant of each panel...
Includes: Supplementary data